Abstract
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia-in particular, maturing data on the use of imatinib in different phases of the disease; the optimal therapy of newly diagnosed patients; the emergence of resistance to imatinib and potential strategies to overcome this problem; and finally, the place of stem cell transplantation in current treatment algorithms.
| Original language | English |
|---|---|
| Pages (from-to) | 10-15 |
| Number of pages | 6 |
| Journal | Current Opinion in Oncology |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2003 |
| Externally published | Yes |
